Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Reduction in Platelet Counts May Predict the Development of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 1748.

https://doi.org/10.1182/blood-2024-202937

Published: 2024

Journal Articles

Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project

Blood (2024) 144 (Supplement 1): 237.

https://doi.org/10.1182/blood-2024-201441

Published: 2024

Journal Articles

Epcoritamab for Relapsed/Refractory B Cell Lymphoma - the Israeli Real-World Experience of a Compassionate Use Program

Shlomzion Aumann, Abraham Avigdor, Ronit Marcus, Netanel A. Horowitz, Ronit Gurion, Tamar Tadmor, Roy Vitkon, May Meira Basood, Uri Abadi, Meirav Kedmi

Blood (2024) 144 (Supplement 1): 5124.

https://doi.org/10.1182/blood-2024-198926

Published: 2024

Journal Articles

Platelet-Based Dose-Adjusted Low Molecular Weight Heparin Treatment Is Efficacious and Safe in Newly Diagnosed Acute Leukemia Patients with Catheter-Related Thrombosis

Shay Perek, Niv Izhaki, Benjamin Brenner, Tamar Katz, Netanel A. Horowitz

Blood (2023) 142 (Supplement 1): 4027.

https://doi.org/10.1182/blood-2023-185544

Published: 2023

Journal Articles

Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 855.

https://doi.org/10.1182/blood-2023-177588

Published: 2023

Journal Articles

Efficacy and Safety of Glofitamab in Patients with R/R DLBCL in Real Life Setting - a Retrospective Study

Ronit Gurion, Dmitri Guz, Meirav Kedmi, Chava Perry, Irit Avivi Mazza, Netanel A. Horowitz, Uri Abadi, Anat Gafter-Gvili, Pia Raanani, Neta Goldschmidt, Boaz Nachmias, Shlomzion Aumann

Blood (2023) 142 (Supplement 1): 5170.

https://doi.org/10.1182/blood-2023-186033

Published: 2023

Journal Articles

Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Adam J. Olszewski, Abraham Avigdor, Sunil Babu, Itai Levi, Herbert Eradat, Uri Abadi, Houston Holmes, Matthew McKinney, Dariusz Woszczyk, Krzysztof Giannopoulos, Wojciech Jurczak, Diana Dunshee, Annie Yang, Mingzhu Zhou, Naseer Qayum, Gila Sellam, Netanel A. Horowitz

Blood (2022) 140 (Supplement 1): 1778–1780.

https://doi.org/10.1182/blood-2022-157768

Published: 2022

Journal Articles

Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era

Theodoros P. Vassilakopoulos, Fotios Panitsas, Zois Mellios, John Apostolidis, Alexia Piperidou, Michalis D Michael, Ronit Gurion, Meltem Akay, Eleftheria Hatzimichael, Stamatis J. Karakatsanis, Maria Dimou, Christina Kalpadakis, Eirini Katodritou, Theoni Leonidopoulou, Ioannis Kotsianidis, Chara Giatra, Nikolaos Kanellias, Ayman Sayyed, Tamar Tadmor, Leylagul Kaynar, Miri Zektser, Argiris Symeonidis, SC Atalar, Evgenia Verrou, Odit Gutwein, Chezi Ganzel, Giorgos Karianakis, Jonathan Isenberg, Gabriela Gainaru, Theodora Triantafyllou, Efimia Vrakidou, Maria Palassopoulou, Mehmet Ozgur, Semra Paydas, Panagiotis Tsirigotis, Maria Tsirogianni, Tulin Tuglular, Chrysovalantou Chatzidimitriou, Maria Kotsopoulou, Evangelos Terpos, Panagiotis Zikos, Argyro Koumarianou, Christos Poziopoulos, Dimitrios Boutsis, Anat Gafter-Gvili, Themistoklis Karmiris, Maria K. Angelopoulou, Maria Bakiri Papaioannou, Gerassimos Pangalis, Panayiotis Panayiotidis, Burhan Ferhanoglu, Netanel A. Horowitz, Sotirios Papageorgiou

Blood (2022) 140 (Supplement 1): 9554–9556.

https://doi.org/10.1182/blood-2022-168627

Published: 2022

Journal Articles

Administration of Obinutuzumab, and Not Rituximab, during Induction and Maintenance for Follicular Lymphoma Increases the Likelihood of Developing Delayed Neutropenia

Shimrit Harlev, Nashwa Fadaos, Tehila Azoulay, Ronit Leiba, Nurit Horesh, Tsofia Inbar, Netanel A. Horowitz, Inna Tsoran-Rosenthal, Noa Lavi, Eldad J. Dann, Tsila Zuckerman

Blood (2022) 140 (Supplement 1): 6534–6535.

https://doi.org/10.1182/blood-2022-166233

Published: 2022

Journal Articles

Patients with Hodgkin Lymphoma Develop Adequate Humoral Serological Response to Vaccination with Two Doses of BNT162b2

Eldad J Dann, Tsofia Inbar, Tania Mashiach, Jamela Eisa, Shimrit Ringelstein Harlev, Netanel A Horowitz

Blood (2021) 138 (Supplement 1): 2458.

https://doi.org/10.1182/blood-2021-149379

Published: 2021

Journal Articles

Myeloid-Derived Suppressor Cells As Potential Contributors to Pregnancy-Associated Lymphoma Progression

Netanel A Horowitz, MD, Noam Bettman, PhD, Ali Abd El Wahed, Tamar Katz, PhD

Blood (2019) 134 (Supplement_1): 3979.

https://doi.org/10.1182/blood-2019-124292

Published: 2019

Journal Articles

Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study

Svetlana Trestman, MD, Chezi Ganzel, MD, Shai Levi, MSc, Moshe E. Gatt, MD, Noa Lavi, MD, Iuliana Vaxman, MDBA, Ory Rouvio, MD, Hila Magen, MD, Netanel A Horowitz, MD, Merav Leiba, MD, Tamar Tadmor, MD, Katrin Herzog Tzarfati, MD, Celia Surio, MD, Shay Yeganeh, MD, Nagib Deli, MD, Irit Avivi, MD, Cohen Yael, Dr.

Blood (2019) 134 (Supplement_1): 3180.

https://doi.org/10.1182/blood-2019-128325

Published: 2019

Journal Articles

BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study

Tsila Zuckerman, MD, Ron Ram, MD, Maya Koren-Michowitz, MD, Luiza Akria, MD, Ron Hoffman, Israel Henig, MD, Yishai Ofran, MD, Noa Lavi, MD, Netanel A Horowitz, MD, Olga Nudelman, MD, Shay Yeganeh, MD, Stela Gengrinovitch, PhD, Liat Flaishon, PhD MD, Ruth Ben Yakar, PhD, Jacob M. Rowe, MD

Blood (2017) 130 (Supplement 1): 893.

https://doi.org/10.1182/blood.V130.Suppl_1.893.893

Published: 2017

Journal Articles

Characteristics, Management and Outcome of DLBCL Patients Presenting with Simultaneous Systemic and CNS Disease at Diagnosis - a Retrospective Multicenter Study

Sharon Ben Barouch, MD, Yair Herishanu, MD, Nadav Sarid, MD, Chava Perry, Irit Avivi, MD, Lev Shvidel, MD, Osnat Bairey, MD, Noa Lavi, MD, Netanel A Horowitz, MD, Abraham Avigdor, MD, Neta Goldschmidt, MD, Eyal Lebel, MD, Orit Sofer

Blood (2017) 130 (Supplement 1): 1563.

https://doi.org/10.1182/blood.V130.Suppl_1.1563.1563

Published: 2017

Journal Articles

Published abstracts at international meetings often over- or underestimate the initial response rate

Ofrat Beyar-Katz, Jacob M. Rowe, Lauren E. Townsend, Martin S. Tallman, Rivka Hadomi, Netanel A. Horowitz

Blood (2017) 129 (16): 2326–2328.

https://doi.org/10.1182/blood-2017-01-763144

Published: 2017

Includes: Supplemental data

Journal Articles

Astarabine, a Novel Leukemia-Targeted Cytarabine Composition Allows, for the First Time, the Delivery of High Cytarabine Doses for Older or Unfit Patients with Acute Leukemia. Results of an Ongoing Phase I/IIa Study

Tsila Zuckerman, MD, Stela Gengrinovitch, PhD, Ruth Ben-Yakar, PhD, Ron Hoffman, MD, Israel Henig, MD, Noa Lavi, MD, Luiza Akria, MD, Yishai Ofran, MD, Netanel A Horowitz, MD, Olga Nudelman, MD, Maya Koren-Michowitz, MD, Shay Yeganeh, MD, Martin S. Tallman, MD, Jacob M. Rowe, MD

Blood (2016) 128 (22): 1650.

https://doi.org/10.1182/blood.V128.22.1650.1650

Published: 2016

Journal Articles

Primary Plasma Cell Leukemia Has a Poor Prognosis Even in the Era of Novel Agents - a Multicenter Case Series

Chezi Ganzel, Ory Rouvio, MD, Hila Magen, MD, Osnat Jarchowsky, Irit Avivi, MD, Katrin Herzog, Cohen Yossi, Tamar Tadmor, MD, Netanel A Horowitz, MD, Merav Leiba, MD, Arnon Nagler, MD MSc, Yael Cohen, MD, Shlomo Bulvik, MD, Dina Ben Yehuda, MD, Jacob M. Rowe, MD, Moshe E. Gatt, MD

Blood (2016) 128 (22): 5699.

https://doi.org/10.1182/blood.V128.22.5699.5699

Published: 2016

Journal Articles

Beac and BEAM High-Dose Chemotherapy in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation Are Efficacious, with Comparable Toxicity

Noa Lavi, MD, Ron Ram, MD, Odelia Amit, MD, Netanel A Horowitz, MD, Tzila Zuckerman, MD

Blood (2016) 128 (22): 5828.

https://doi.org/10.1182/blood.V128.22.5828.5828

Published: 2016

Journal Articles

TLR9-Regulated IL10 Mediates Immune Inhibitory Activity of Chronic Lymphocytic Leukemia B-Cells

Shimrit Ringelstein-Harlev, MD PhD, Mona Fanadka, BSc, Netanel A. Horowitz, MD, Irit Avivi, MD, Tami Katz, PhD

Blood (2016) 128 (22): 4377.

https://doi.org/10.1182/blood.V128.22.4377.4377

Published: 2016

Journal Articles

Addition of Intermediate-Dose Methotrexate Is Beneficial in Terms of Both Progression-Free Survival and Overall Survival for Patients with Diffuse Large B Cell Lymphoma Receiving Either R-CHOP or CHOP

Eldad J. Dann, MD, Neta Goldschmidt, MD, Vered Heffes, MD, Tanya Mashiach, MSc, Moshe E. Gatt, MD, Netanel A Horowitz, MD

Blood (2016) 128 (22): 1877.

https://doi.org/10.1182/blood.V128.22.1877.1877

Published: 2016

NARROW

Reduction in Platelet Counts May Predict the Development of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma

Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project

Epcoritamab for Relapsed/Refractory B Cell Lymphoma - the Israeli Real-World Experience of a Compassionate Use Program

Platelet-Based Dose-Adjusted Low Molecular Weight Heparin Treatment Is Efficacious and Safe in Newly Diagnosed Acute Leukemia Patients with Catheter-Related Thrombosis

Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Efficacy and Safety of Glofitamab in Patients with R/R DLBCL in Real Life Setting - a Retrospective Study

Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era

Administration of Obinutuzumab, and Not Rituximab, during Induction and Maintenance for Follicular Lymphoma Increases the Likelihood of Developing Delayed Neutropenia

Patients with Hodgkin Lymphoma Develop Adequate Humoral Serological Response to Vaccination with Two Doses of BNT162b2

Myeloid-Derived Suppressor Cells As Potential Contributors to Pregnancy-Associated Lymphoma Progression

Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study

BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study

Characteristics, Management and Outcome of DLBCL Patients Presenting with Simultaneous Systemic and CNS Disease at Diagnosis - a Retrospective Multicenter Study

Published abstracts at international meetings often over- or underestimate the initial response rate

Astarabine, a Novel Leukemia-Targeted Cytarabine Composition Allows, for the First Time, the Delivery of High Cytarabine Doses for Older or Unfit Patients with Acute Leukemia. Results of an Ongoing Phase I/IIa Study

Primary Plasma Cell Leukemia Has a Poor Prognosis Even in the Era of Novel Agents - a Multicenter Case Series

Beac and BEAM High-Dose Chemotherapy in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation Are Efficacious, with Comparable Toxicity

TLR9-Regulated IL10 Mediates Immune Inhibitory Activity of Chronic Lymphocytic Leukemia B-Cells

Addition of Intermediate-Dose Methotrexate Is Beneficial in Terms of Both Progression-Free Survival and Overall Survival for Patients with Diffuse Large B Cell Lymphoma Receiving Either R-CHOP or CHOP

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only